Written by Fatima Yasser
Friday, March 24, 2023 01:00 PM
A research team at the Department of Pharmacy of the University of Hong Kong Medical School discovered that SGLT2 inhibitors, also called gliflozins, a class of drugs that prevent glucose reabsorption in the kidneys and thus lower blood sugar. It can reduce the risks of renal and respiratory diseases, including end stage renal disease, obstructive airway disease and pneumonia in a retrospective cohort study.
These studies provide new evidence that SGLT2 inhibitors can confer additional glycemic protection in patients with SGLT2.diabetic Type 2 and potentially a better alternative to an older class of glucose-lowering drugs, e.g. The discovery has been published in the journal Endocrinology & Metabolism and JAMA Open Network. According to the Science Alert website.
SGLT2 inhibitors are a new class of second-line glucose-lowering drugs for type 2 diabetes. Placebo-controlled clinical trials and multinational observational studies have shown that, along with glycemic control, SGLT2 inhibitors provide , also cardiovascular and renal protection for patients with type 2 diabetes over the past few years.
However, it is not clear whether SGLT2 inhibitors can provide better cardiorenal protection when compared to individual classes of older glucose-lowering drugs that have been widely prescribed in recent years. A study was conducted to investigate the association of SGLT2 inhibitors with 4 renal outcomes, namely ESRD, albuminuria, acute renal failure (ARF), and decrease in estimated glomerular filtration rate.
The team also conducted another cohort study to investigate the association of SGLT2 inhibitors with pneumonia risk because activating SGLT2 inhibitors have been shown to treat pneumonia, which has been implicated in both asthmatic airway inflammation and chronic obstructive pulmonary disease.